Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allopurinol + ascorbic acid
- Development stage
- Preclinical
- Lead developer
- Ironwood Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of allopurinol, a xanthine oxidase inhibitor that reduces uric acid production, and ascorbic acid (vitamin C), an antioxidant vitamin. This combination has been studied for its effects on uric acid levels in gout patients and for potential cardiovascular benefits. Research indicates that while allopurinol effectively lowers uric acid levels, adding vitamin C provides only minimal additional urate-lowering effects in patients with established gout.
- Other names
- allopurinol + vitamin C
02
Targets
XO (Xanthine Oxidoreductase)
Beyond the preview
Go deeper on allopurinol + ascorbic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allopurinol + ascorbic acid.